Evidence map›Paper›PMID 22752423›Full record

ArticleJournal of gastrointestinal cancer2012

Treatment Response After Unusual Low Dose Sorafenib: Diagnosis with Perfusion CT and Follow-up in a Patient with Recurrent Hepatocellular Carcinoma.

Rodolfo Sacco, Lorenzo Faggioni, Irene Bargellini, Antonio Romano, Marco Bertini, Barbara Ginanni, Valentina Battaglia, Michele Bertoni, Elena Bozzi, Graziana Federici and 7 more

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in Journal of gastrointestinal cancer, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Rodolfo SaccoGastroenterology Department, Pisa University Hospital, Via Paradisa 2, 56124, Pisa, Italy. r.sacco@ao-pisa.toscana.it.
Lorenzo FaggioniDepartment of Diagnostic and Interventional Radiology, Pisa University Hospital, Pisa, Italy.
Irene BargelliniDepartment of Diagnostic and Interventional Radiology, Pisa University Hospital, Pisa, Italy.
Antonio RomanoGastroenterology Department, Pisa University Hospital, Via Paradisa 2, 56124, Pisa, Italy.
Marco BertiniGastroenterology Department, Pisa University Hospital, Via Paradisa 2, 56124, Pisa, Italy.
Barbara GinanniDepartment of Diagnostic and Interventional Radiology, Pisa University Hospital, Pisa, Italy.
Valentina BattagliaDepartment of Diagnostic and Interventional Radiology, Pisa University Hospital, Pisa, Italy.
Michele BertoniGastroenterology Department, Pisa University Hospital, Via Paradisa 2, 56124, Pisa, Italy.
Elena BozziDepartment of Diagnostic and Interventional Radiology, Pisa University Hospital, Pisa, Italy.
Graziana FedericiGastroenterology Department, Pisa University Hospital, Via Paradisa 2, 56124, Pisa, Italy.
Salvatore MetrangoloGastroenterology Department, Pisa University Hospital, Via Paradisa 2, 56124, Pisa, Italy.
Giuseppe ParisiGastroenterology Department, Pisa University Hospital, Via Paradisa 2, 56124, Pisa, Italy.
Emanuele NeriDepartment of Diagnostic and Interventional Radiology, Pisa University Hospital, Pisa, Italy.
Elisabetta SodiniGastroenterology Department, Pisa University Hospital, Via Paradisa 2, 56124, Pisa, Italy.
Emanuele TuminoGastroenterology Department, Pisa University Hospital, Via Paradisa 2, 56124, Pisa, Italy.
Giampaolo BresciGastroenterology Department, Pisa University Hospital, Via Paradisa 2, 56124, Pisa, Italy.
Carlo BartolozziDepartment of Diagnostic and Interventional Radiology, Pisa University Hospital, Pisa, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AgedAntineoplastic AgentsCarcinoma, HepatocellularDose-Response Relationship, DrugFemaleFollow-Up StudiesHumansLiver NeoplasmsNeoplasm Recurrence, LocalNiacinamidePhenylurea CompoundsPrognosisSorafenibTomography, X-Ray ComputedAntineoplastic AgentsNiacinamidePhenylurea CompoundsSorafenib

Identifiers

PMID22752423

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.